Drug use evaluation of antidyslipidemic agents at a community hospital in Japan

Yakugaku Zasshi

Volumn 122, Issue 7, 2002, Pages 499-506

  Ujita, Kazuko ^a   Ohno, Keiko ^b   Hashiguchi, Masayuki ^b   Echizen, Hirotoshi ^b   Rikihisa, Tadaaki ^b   Ogata, Hiroyasu ^b  

^a Dept of Hospital Pharmacy   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Coronary heart disease; Dyslipidemias; LDL cholesterol; Pharmacotherapy; Risk factors; Total cholesterol

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; BILE ACID RESIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMMUNITY HOSPITAL; DRUG USE; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL STAFF; OBESITY; OUTPATIENT; PHENOTYPE; PHYSICIAN; PRACTICE GUIDELINE; RECORDING; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; CLASSIFICATION; CORONARY ARTERY DISEASE; HYPERLIPIDEMIA; MIDDLE AGED; STANDARD; STATISTICS;

AGED; ANTILIPEMIC AGENTS; CORONARY DISEASE; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HOSPITALS, COMMUNITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; JAPAN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0036631595     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi.122.499     Document Type: Article

References (17)

1. Kannel W. B., Castelli W. P., Gordon T., McNamara P. M., Ann. Intern. Med., 74, 1-12 (1971).
2. Stamler J., Wentworth D., Neaton J. D., JAMA, 256, 2823-2828 (1986).
3. Pharma Marketing Survey Res. Lab., "The Estimated Market of the Ethics Drugs for Cardiovascular Disease in 1997, Yakuji Handbook," Jiho Ltd., Tokyo, 1998, p. 279.
4. Sueta C. A., Chowdhury M., Boccuzzi S. J., Smith S. C., Alexander C. M., Londhe A., Lulla A., Simpson R. J., Am. J. Cardiol., 83,1303-1307 (1999).
5. Expert Panel on Decision, "Evaluation and the Treatment of High Blood Cholesterol in Adults," JAMA, 269, 3015-3023 (1993).
6. Matsuzaki M., Kita T., Mabuchi H., Matsuzaki Y., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H., The JLIT Study Group, Abstracts of papers, 50th Annual Scientific Session of American College of Cardiology, Orlando, March 2001, 263A.
7. McNeil J. J., Krum H., "Cardiovascular Disorders," Avery's Drug Treatment ed. by Speight T. M., Holford N. H. G., ADIS International Ltd., Auckland, 1997, pp. 819-820.
8. Lipid Research Clinics Program, JAMA, 251,351-364 (1984).
9. Bristol-Myers Squibb K. K. (1999).
10. Hata Y., Shigematsu H., Tsushima M., Oikawa T., Yamauchi Y., Yamamoto M., Hirose N., Goto Y., Honda M., Ogino T., Kimura M., Shimada H., Satowa S., Hirai M., Ohkawa H., Maruyama T., Hayashi S., Kodama R., Umetada Y., Mori K., Onizuka T., Koizumi K., Ohkubo K., Okajima S., Fujimori I., Sekita K., Tsunashima K., Kawamura A., Tsuchida T., Shibuya K., Geriat. Med., 19,855-872 (1981).
11. Kukita H., Hiwada K., Therapeutic Research,14, 551-558 (1994).
12. Ericsson C. G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U., Lancet, 347, 849-853 (1996).
13. Israeli Society for Prevention of Heart Attacks, Circulation, 102, 21-27 (2000).
14. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias, Japan Atherosclerosis Society, The Journal of Japan Atherosclerosis Society, 25, 1-34(1997).
15. Frolkis J. P., Zyzanski S. J., Schwartz J. M., Suhan P. S., Circulation, 98, 851-855 (1998).
16. Danias P. G., O'Mahony S., Radford M. J., Korman L., Silverman D. I., Am. J. Cardiol.,81, 1353-1356 (1998).
17. Majumdar S. R., Gurwitz J. H., Soumerai S. B., J. Gen. Intern. Med., 14, 711-717 (1999).